STOCK TITAN
  1. Home
  2. Sec-filings
  3. NVCR
  4. [Form 4] NovoCure Ltd Insider Trading Activity

NovoCure (NASDAQ: NVCR) director granted RSUs and options in new equity awards

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
4

Rhea-AI Filing Summary

NovoCure Ltd director Gabriel Leung received new equity awards as part of compensation. He was granted 11,610 Ordinary Shares in the form of restricted stock units at no cost, increasing his direct holdings to 101,109 Ordinary Shares.

He also received stock options for 16,999 Ordinary Shares at an exercise price of $16.15 per share, expiring on June 3, 2036. Both the restricted stock units and the options are scheduled to vest 100% on the earlier of the first anniversary of the June 3, 2026 grant date or the day immediately preceding NovoCure's 2027 annual general meeting of shareholders.

Positive

  • None.

Negative

  • None.
Insider LEUNG GABRIEL
Role null
Type Security Shares Price Value
Grant/Award Stock Option (Right to Buy) 16,999 $0.00 --
Grant/Award Ordinary Shares 11,610 $0.00 --
Holdings After Transaction: Stock Option (Right to Buy) — 16,999 shares (Direct, null); Ordinary Shares — 101,109 shares (Direct, null)
Footnotes (1)
  1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Restricted stock units granted 11,610 Ordinary Shares Grant of restricted stock units on June 3, 2026
Shares held after grant 101,109 Ordinary Shares Total direct holdings following RSU grant
Stock options granted 16,999 options Options on Ordinary Shares granted June 3, 2026
Option exercise price $16.15 per share Exercise price for 16,999 stock options
Option expiration date June 3, 2036 Expiration of granted stock options
restricted stock units financial
"Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates"
Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.
stock options financial
"Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates"
Stock options are agreements that give a person the right to buy or sell a company's stock at a specific price within a certain time frame. They are often used as a reward or incentive, similar to a coupon that can be used later if the stock price rises, allowing the holder to make a profit.
exercise price financial
"Options to buy ordinary shares include a conversion or exercise price of 16.1500 per share"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
annual general meeting of shareholders financial
"the day immediately preceding the Company's 2027 annual general meeting of shareholders"
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
Form 4 Insider Transactions: What Each Field Means →
SEC Form 4
FORM 4UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940
OMB APPROVAL
OMB Number:3235-0287
Estimated average burden
hours per response:0.5
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.
1. Name and Address of Reporting Person*
LEUNG GABRIEL
(Last)(First)(Middle)
C/O NOVOCURE INC.
1550 LIBERTY RIDGE DRIVE, SUITE 115
(Street)
WAYNE PENNSYLVANIA 19087
(City)(State)(Zip)
UNITED STATES
(Country)		2. Issuer Name and Ticker or Trading Symbol
NovoCure Ltd [ NVCR ] 		5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
XDirector10% Owner
Officer (give title below)Other (specify below)
2a. Foreign Trading Symbol
3. Date of Earliest Transaction (Month/Day/Year)
06/03/2026		6. Individual or Joint/Group Filing (Check Applicable Line)
XForm filed by One Reporting Person
Form filed by More than One Reporting Person
4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year)2A. Deemed Execution Date, if any (Month/Day/Year)3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeVAmount(A) or (D)Price
Ordinary Shares(1)06/03/2026A11,610A$0.00101,109D
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year)3A. Deemed Execution Date, if any (Month/Day/Year)4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year)7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (Right to Buy)$16.1506/03/2026A16,99906/03/2027(2)06/03/2036Ordinary Shares16,999$0.0016,999D
Explanation of Responses:
1. Represents restricted stock units that are scheduled to vest 100% on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
2. Options to buy ordinary shares will fully vest and become exercisable on the earlier of the following dates: (i) the first anniversary of the grant date or (ii) the day immediately preceding the Company's 2027 annual general meeting of shareholders.
Remarks:
Steven Robbins, as attorney in fact for Leung, Gabriel06/05/2026
** Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What did NovoCure (NVCR) director Gabriel Leung receive in this Form 4 filing?

Gabriel Leung received two equity awards: 11,610 restricted stock units and stock options for 16,999 Ordinary Shares. Both awards were granted at no cash cost to him as part of his director compensation.

How many NovoCure (NVCR) shares does Gabriel Leung hold after these grants?

After the grant, Gabriel Leung directly holds 101,109 Ordinary Shares of NovoCure. This figure includes his newly granted 11,610 restricted stock units, reflecting his updated equity position as reported in the Form 4 filing.

What are the key terms of Gabriel Leung’s NovoCure stock options?

Leung’s stock options cover 16,999 Ordinary Shares at an exercise price of $16.15 per share. These options fully vest on the specified vesting date and expire on June 3, 2036 if not exercised.

When do Gabriel Leung’s NovoCure restricted stock units and options vest?

Both the restricted stock units and stock options vest 100% on the earlier of two dates: the first anniversary of the June 3, 2026 grant date or the day immediately preceding NovoCure’s 2027 annual general meeting of shareholders.

Did Gabriel Leung buy or sell NovoCure (NVCR) shares on the open market?

The Form 4 shows grant or award acquisitions, not open-market trades. Leung received restricted stock units and options as compensation; there were no reported purchases or sales on the open market in this filing.

What type of securities are covered in Gabriel Leung’s NovoCure Form 4?

The filing covers Ordinary Shares and stock options. Leung received 11,610 Ordinary Shares via restricted stock units and stock options for 16,999 Ordinary Shares, both subject to the same time-based vesting schedule.